REG - BiVictriX Therapcts. - BiVictriX CFO appointment

Bivictrix TherapeuticsAnnouncement

06/01/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220106:nRSF5744Xa&default-theme=true

RNS Number : 5744X  BiVictriX Therapeutics PLC  06 January 2022

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK
VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH
LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED.  ON
PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS
INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

 

BIVICTRIX THERAPEUTICS PLC

("BiVictriX" or "the Company")

 

Appointment of Glyn Baker as Chief Financial Officer

 

Alderley Park, 6 January 2022 - BiVictriX Therapeutics plc (AIM: BVX), an
emerging biotechnology company applying a novel approach to develop next
generation cancer therapies using insights derived from frontline clinical
experience, today announces that it has appointed Glyn Baker as Chief
Financial Officer, in a non-board role.

 

Glyn has worked in the biotechnology industry for around 20 years, initially
as a financial and IT consultant before moving to various senior finance
management roles. Most recently, Glyn has been involved in establishing a new
Cambridge, UK based start-up in the neurodegenerative disease space.

Prior to this, Glyn was Finance Director of drug discovery company Inflazome
Ltd ("Inflazome"). In his role there, Glyn successfully managed a €40m
Series B investment round and arranged a US$20m venture debt facility with
Oxford Finance LLP based in Boston in the US. In 2020, Inflazome was bought by
Roche for an upfront payment of US$450m plus substantial milestones. Glyn was
part of the Inflazome board sub-committee managing relationships with
investors, potential exit partners and a range of intermediaries.

Before Glyn joined Inflazome he was the CFO of TwistDx Ltd ("TwistDx").
TwistDx was sold to Alere, Inc. in March 2010, which was subsequently acquired
by Abbott Laboratories, Inc. in February 2016.

Ms Laura Brogden, the Company's Financial Controller, will remain with
BiVictriX for a period of three months to ensure an orderly handover of
responsibilities to Glyn Baker.

Tiffany Thorn, Chief Executive of BiVictriX, commented: "We are delighted to
welcome Glyn Baker to BiVictriX as Chief Financial Officer. Glyn has amassed
significant expertise in Finance and M&A over the last 20 years with some
impressive accomplishments. This  knowledge, coupled with his contacts, will
be invaluable as we look to grow our business and progress the development of
our Bi-Cygni® therapeutics."

 

Glyn Baker, BiVictriX's new Chief Financial Officer, added: "I was
particularly attracted to BiVictriX due to the quality of the science, the
leadership team and the Board of directors. I look forward to supporting
Tiffany and the broader team as the Company progresses the development of its
key work programmes."

 

   For more information, please contact:

BiVictriX Therapeutics plc
 Tiffany Thorn, Chief Executive Officer

 Iain Ross, Chairman                                Email: info@bivictrix.com (mailto:info@bivictrix.com)

 SP Angel Corporate Finance LLP (NOMAD and Broker)  Tel: +44 (0) 20 3470 0470
 David Hignell, Caroline Rowe (Corporate Finance)

 Vadim Alexandre, Rob Rees (Sales and Broking)

 Panmure Gordon (UK) Limited (Joint Broker)         Tel: +44 (0) 20 7886 2500
 Rupert Dearden/Freddy Crossley/Emma Earl

 Consilium Strategic Communications
 Ashley Tapp, Suki Virji                            Tel: +44 (0) 20 3709 5700

                           Email: Bivictrix@consilium-comms.com (mailto:Bivictrix@consilium-comms.com)

 

About BiVictriX Therapeutics plc

BiVictriX is a UK-based drug discovery and development company which is
focused on leveraging clinical experience to develop a class of highly
selective, next generation cancer therapeutics which exhibit superior potency,
whilst eliminating treatment-related toxicities.

 

The Company utilises a first-in-class approach to generate a proprietary
pipeline of Bi-Cygni® therapeutics which are designed to selectively target
antigen co-expression fingerprints, or "twin antigens", on tumour cells, which
are largely absent from healthy cells. Whereas this concept has been validated
in a clinical diagnostic setting to support the diagnosis and monitoring of
haematological cancers, it has not yet been widely used in a therapeutic
setting.

 

BiVictriX has identified a diverse panel of novel cancer-specific "twin
antigens", across a broad range of cancer indications including Diffuse Large
B Cell Lymphoma, Acute Myeloid Leukaemia and Blastic Plasmacytoid Dendritic
Cell Neoplasm. The Company is using these novel "twin-antigens" to develop
more effective and safer therapeutics to target cancers that are expected to
constitute orphan indications and currently constitute areas of high unmet
medical need.

 

Find out more about BiVictriX online at www.bivictrix.com
(http://www.bivictrix.com/)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCDGGDBXUGDGDU